Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal blood biomarker cohort in moderate-to-severe atopic dermatitis
NL-OMON51834Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label trial of cyclosporine, dupilumab, tralokinumab, abrocitinib and upadacitinib in atopic dermatitis (AD) (5 cohorts), sponsored by Erasmus MC. Primary endpoint: Primary biomarker endpoint. Planned start May 2022; status: not yet recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON51834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51834.